0.8872
Sutro Biopharma Inc stock is traded at $0.8872, with a volume of 362.04K.
It is down -3.04% in the last 24 hours and up +10.17% over the past month.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
See More
Previous Close:
$0.915
Open:
$0.93
24h Volume:
362.04K
Relative Volume:
0.27
Market Cap:
$74.93M
Revenue:
$153.73M
Net Income/Loss:
$-106.79M
P/E Ratio:
-0.4984
EPS:
-1.78
Net Cash Flow:
$-115.93M
1W Performance:
+16.74%
1M Performance:
+10.17%
6M Performance:
-56.51%
1Y Performance:
-79.30%
Sutro Biopharma Inc Stock (STRO) Company Profile
Name
Sutro Biopharma Inc
Sector
Industry
Phone
650-392-8412
Address
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
STRO
Sutro Biopharma Inc
|
0.8872 | 77.28M | 153.73M | -106.79M | -115.93M | -1.78 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-16-25 | Upgrade | Piper Sandler | Neutral → Overweight |
Mar-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
Mar-14-25 | Downgrade | BofA Securities | Buy → Underperform |
Mar-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
Mar-14-25 | Downgrade | Wedbush | Outperform → Neutral |
May-08-24 | Initiated | BofA Securities | Buy |
Nov-09-23 | Initiated | Deutsche Bank | Buy |
Oct-06-23 | Initiated | Oppenheimer | Outperform |
Mar-21-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Aug-18-22 | Resumed | Wells Fargo | Overweight |
Jun-18-21 | Initiated | H.C. Wainwright | Buy |
Dec-03-20 | Initiated | Stifel | Buy |
Sep-02-20 | Initiated | Jefferies | Buy |
Jul-16-20 | Initiated | Wells Fargo | Overweight |
Jan-13-20 | Initiated | SunTrust | Buy |
Oct-07-19 | Initiated | BTIG Research | Buy |
Jul-18-19 | Initiated | Deutsche Bank | Buy |
Apr-29-19 | Initiated | H.C. Wainwright | Buy |
Oct-22-18 | Initiated | JMP Securities | Mkt Outperform |
Oct-22-18 | Initiated | Piper Jaffray | Overweight |
Oct-22-18 | Initiated | Wedbush | Outperform |
View All
Sutro Biopharma Inc Stock (STRO) Latest News
What makes Sutro Biopharma Inc. stock price move sharplyGet timely alerts on market movers - jammulinksnews.com
Key External Factors That Drive Sutro Biopharma Inc. Stock Price MovementsMomentum Buy Alert - Newser
What are the technical indicators suggesting about Sutro Biopharma Inc.High-yield investments - jammulinksnews.com
Why Sutro Biopharma Inc. stock attracts strong analyst attentionParabolic Move Ideas - Newser
What analysts say about Sutro Biopharma Inc. stockFree Capital Allocation Plans - PrintWeekIndia
Sutro Biopharma Inc. Stock Analysis and ForecastFree Capital Growth Strategies - Autocar Professional
How Sutro Biopharma Inc. stock reacts to Fed policy changesUnrivaled growth potential - jammulinksnews.com
Here's Why Sutro Biopharma (NASDAQ:STRO) Must Use Its Cash Wisely - Yahoo Finance
What drives Sutro Biopharma Inc. stock priceExplosive capital gains - jammulinksnews.com
Sutro Biopharma partners with FDA to develop ADC reference materials By Investing.com - Investing.com Canada
Sutro Biopharma partners with FDA to develop ADC reference materials - Investing.com Australia
Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates - The Manila Times
FDA Selects Sutro Biopharma's Revolutionary Platform to Shape Future of Cancer Drug Development - Stock Titan
Is Sutro Biopharma Inc. a good long term investmentBreakthrough financial growth - jammulinksnews.com
what makes sutro biopharma inc. stock price move sharplyReal Time Alert Service - Newser
How Sutro Biopharma Inc. stock performs during market volatilityMoney Making Low Risk Plans - Newser
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Vontobel Holding Ltd. Has $33,000 Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma, Inc.(NasdaqGM: STRO) dropped from Russell 2000 Dynamic Index - MarketScreener
Sutro Biopharma Faces NASDAQ Non-Compliance Notice - TipRanks
Sutro Biopharma (NASDAQ:STRO) Upgraded to Overweight at Piper Sandler - Defense World
Sutro Biopharma Inc Stock (STRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sutro Biopharma Inc Stock (STRO) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
May 01 '25 |
Option Exercise |
0.00 |
37,849 |
0 |
133,282 |
Srinivasan Venkatesh | CHIEF TECH OP OFFICER |
May 01 '25 |
Option Exercise |
0.00 |
2,500 |
0 |
54,580 |
Borgman Anne Elizabeth | CHIEF MEDICAL OFFICER |
May 01 '25 |
Option Exercise |
0.00 |
69,063 |
0 |
122,161 |
Srinivasan Venkatesh | CHIEF TECH OP OFFICER |
Apr 11 '25 |
Option Exercise |
0.00 |
21,250 |
0 |
59,683 |
NEWELL WILLIAM J | CEO |
Mar 05 '25 |
Option Exercise |
0.00 |
18,750 |
0 |
299,239 |
FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 05 '25 |
Option Exercise |
0.00 |
8,750 |
0 |
99,027 |
ALBINI EDWARD C | CFO AND SECRETARY |
Mar 05 '25 |
Option Exercise |
0.00 |
8,750 |
0 |
135,675 |
FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 04 '25 |
Option Exercise |
0.00 |
9,125 |
0 |
94,025 |
NEWELL WILLIAM J | CEO |
Mar 04 '25 |
Option Exercise |
0.00 |
31,125 |
0 |
291,625 |
Chung Jane | PRESIDENT AND COO |
Mar 04 '25 |
Option Exercise |
0.00 |
7,875 |
0 |
100,642 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):